ERP — on-the-record assessments

The counter-ion determination appeared on the certificate with the method named, so the declared mass can be resolved into peptide and salt. They switched to a phase-change pack for the reorder without being asked and it arrived hard, and documentation for lot ERP-26-795 was complete at first issue. Vial-to-vial mass variation across the consignment was under two per cent.

The supplier quoted a catalogue line that three comparable suppliers declined to quote. Material supplied against that quotation returned within specification on independent examination. Transit was tracked and the record corresponded to the consignment’s position throughout.

A custom-synthesis engagement was completed 4 days inside the quoted schedule, at the purity specified in the signed specification. The Janoshik report is held on file and corresponds to the figures published by the supplier.

The order acknowledgement stated the dispatching warehouse, which allows the transit history of the lot to be reconstructed. A signature and release date appear on the certificate. Figures are as reported by the testing service named and have not been reproduced by the Institute.

Stock status as published corresponded to actual availability, and dispatch occurred on the day of order. Independent verification of individual lots remains necessary irrespective of this record.

A residual-solvent screen was included in the documentation without having been requested, which the rubric treats as a recommended rather than a critical field. The supplementary certificate was retrieved without demur. The submission is recorded in full in the evidence log.

The counter-ion was identified and quantified on the certificate, which permits a mass balance to be formed. Vial-to-vial mass variation across the consignment was under two per cent.

The certificate accompanying this consignment satisfies the Institute’s minimum data standard: it carries peptide content stated separately from purity in addition to the critical fields.

Water content is reported by Karl Fischer titration with the determination method named, which the rubric requires and which a minority of suppliers provide. The PeptideMeter report is held on file and corresponds to the figures published by the supplier. The assessor declares no interest in the supplier beyond the transactions described.

Packing was assessed as adequate to the transit undertaken: a tamper strip that had to be cut rather than peeled. Documentation was complete at first issue.

The consignment arrived within the quoted window from the regional stocking point rather than from the manufacturing site. Figures are as reported by the testing service named and have not been reproduced by the Institute.

Across 8 months and 7 orders no substitution, reformulation or post-payment unavailability was encountered by this assessor. The finding covers the lots named and is not generalised beyond them.

The declared figure was not adjusted upward between the certificate and the commercial documentation. Discrepancies of this kind are specifically screened for. Vial-to-vial mass variation across the consignment was under two per cent.

Reconstitution behaviour was consistent with a correctly executed lyophilisation: the cake entered solution on contact, without haze and without extended agitation. The technical response was received within four hours on a working day. The assessor declares no interest in the supplier beyond the transactions described.

Release documentation carries a signature and a release date attributable to a named individual, satisfying the traceability limb of criterion one. The submission is recorded in full in the evidence log.

This assessor has placed 11 orders across 10 months and holds documentation for each. The set is internally consistent. Documentation was complete at first issue.

Consistency across lots was assessed over 12 determinations. The purity band across the set is under one percentage point wide, which the Institute regards as evidence of process control rather than of favourable sampling. Nothing in this submission constitutes medical advice.

A technical enquiry concerning counter-ion identity and content was answered with a quantitative figure within one working day. Responses of this character are recorded because they are uncommon. The supplementary certificate was retrieved without demur. Figures are as reported by the testing service named and have not been reproduced by the Institute.

Purity is declared by a stability-indicating chromatographic method, and the method, column chemistry and detection wavelength are all named on the certificate. The declaration is therefore assessable. Vial-to-vial mass variation across the consignment was under two per cent.

Material obtained directly from the manufacturer returned 98.7%; material of nominally identical description obtained through an intermediary returned 98.4%. The comparison is offered without further comment. Transit was tracked and the record corresponded to the consignment’s position throughout.

Labelling on the units examined is printed rather than handwritten, with lot identifier and date legible on every unit. Identity was confirmed by two orthogonal methods. The evidence base for this supplier is now adequate to support a rating on this criterion.

Documentation was complete at first issue. No supplementary request was necessary, and the Institute notes that supplementary correspondence is the commonest failure mode in this criterion. Documentation was complete at first issue.

Cold-chain integrity was maintained through transit; the phase-change pack remained solid to arrival on day 6. The desiccant sachet was enclosed within the secondary container. The assessor declares no interest in the supplier beyond the transactions described.

Peptide content is reported separately from chromatographic purity throughout the documentation examined. The distinction is maintained consistently across the 12 certificates held. Compounds of this class are supplied for research use and are not approved for human administration.

Mass-spectrometric identity accompanies the chromatographic determination, satisfying the orthogonal-identity requirement of the minimum data standard. Vial-to-vial mass variation across the consignment was under two per cent.

Material for this line was held in regional stock and reached the purchaser without a factory run entering the critical path. Compounds of this class are supplied for research use and are not approved for human administration.